← Home / Generate Biomedicines, Inc. (GENB)
Stock Analysis
Generate Biomedicines, Inc. (GENB)
GENB
GENB · Market data
14.00 -0.21%
Track GENB in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when GENB price is:
52W Range Position
45%
LOWMIDHIGH
Trend
Mixed
Momentum
Neutral
Updated: 2026-08-02 14:45 UTC
WOI Investment Thesis
Mixed
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Insufficient / Negative
✓
Price Structure
Mixed
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
14.19
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
7
●
Financial Results
HIGH
Reports First Quarter 2026 Financial Results and Provides Business Update
(NASDAQ: GENB) (“Generate”) today reported financial results for the first quarter ended March 31, 2026, and highlighted progress across its clinical portfolio.
8-K Filing • SEC EDGAR
What's Driving GENB?
📈 Technical recovery is improving
Momentum is Neutral. Watch 14.19 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 12.58 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
47.9
◎
How to read this setup
The next meaningful technical decision is likely to occur between support at 12.58 and resistance at 14.19. A move through resistance would be needed to materially improve the chart, while a break of support would keep the pressure side dominant.
Price Chart
GENB — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$1.8B
Company size
EV
$1.6B
Debt-adjusted value
P/E
-29.2
Not meaningful
P/S
248.4
Very high
P/B
3.5
Balanced
EV/Sales
227.1
Very high
EV/EBIT
-25.6
Not meaningful
P/FCF
-21.3
Not meaningful
FCF Yield
-4.69%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Negative
≈
Cash Flow
Mixed
⚖
Balance Sheet
Strong
💵 Revenue
7.22M
≈ Insufficient
📈 Net Income
-61.45M
↘ Negative
🧮 EPS (Basic)
-1.07
↘ Negative
Generate Biomedicines, Inc.
Related Opportunities